Lab Crotty
Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance
Rapid germinal center and antibody responses in non-human primates after a single nanoparticle vaccine immunization
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses
Normal human lymph node T follicular helper cells and germinal center B cells accessed via fine needle aspirations
Engineered immunogen binding to alum adjuvant enhances humoral immunity
Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
Targeting HIV Env immunogens to B cell follicles in nonhuman primate through immune complex or protein nanoparticle formulations
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models
Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo
Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors.
HIV vaccinology: 2021 update.
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Adaptive immunity to SARS-CoV-2 and COVID-19.
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
Bcl6-mediated transcriptional regulation of follicular helper T cells (TFH).
AI-guided discovery of the invariant host response to viral pandemics.
Chronic e-cigarette aerosol inhalation alters the immune state of the lungs and increases ACE2 expression, raising concern for altered response and susceptibility to SARS-CoV-2.
Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers.
Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection.
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19.
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
Revealing T follicular helper cells with BCL6.
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells.
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.
SARS-CoV-2 infection generates tissue-localized immunological memory in humans.
Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2.
Phosphate-mediated co-anchoring of RBD immunogens and molecular adjuvants to alum 4 potentiates humoral immunity against SARS-CoV-2
A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.
NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
From structure to sequence: Antibody discovery using cryoEM
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study
Memory B cell development after asymptomatic or mile symptomatic SARS-CoV-2 infection
Mpox vaccine and infection-driven human immune signatures
Design and validation of HIV peptide pools for detection of HIV-specific CD4+ and CD8+ T cell
The transcription factor YY-1 is an essential regulator of T follicular helper cell differentiation
mmunological memory to SARS-CoV-2 infection and COVID-19 vaccines
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease
Long primed germinal centers with enduring affinity maturation and clonal migration
Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status
Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia
Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients
Humoral and cellular immune memory to four COVID-19 vaccines
Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus
Mll1 pioneers histone H3K4me3 deposition and promotes formation of CD8 + T stem cell memory
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Author Correction: The persistence of memory: defining, engineering, and measuring vaccine durability
Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to Variants of Concern
Focusing antibody responses to the fusion peptide in rhesus macaques
The chromatin Rregulator Mll1 supports T follicular helper cell differentiation by controlling expression of Bcl6, LEF-1, and TCF-1
Transcriptional programming of CD4+ TRM differentiation in viral infection balances effector- and memory-associated gene expression
DNA architectural protein CTCF facilitates subset-specific chromatin interactions to limit the formation of memory CD8+ T cells
Author Correction: Long-primed germinal centres with enduring affinity maturation and clonal migration
Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells
A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates
Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2
Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves
Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report
Cytokines in follicular helper T cell Biology in physiologic and pathologic conditions
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback
How COVID-19 ‘breakthrough’ infections alter your immune cells
LA JOLLA, CA—New research from scientists at La Jolla Institute for Immunology (LJI) suggests people who received COVID-19 vaccines and then experienced “breakthrough” infections are especially well armed against future SARS-CoV-2 infections.
Ivy Phung works to build better vaccines
How a Ph.D. student found a place in the intense world of HIV vaccine research
La Jolla Institute for Immunology appoints Shane Crotty, PhD, as Chief Scientific Officer
LJI Professor Shane Crotty, PhD, has been appointed Chief Scientific Officer of La Jolla Institute for Immunology (LJI)
We’ve learned a lot from lymphocytic choriomeningitis virus—now the time has come to fight it
LJI scientists share high-resolution view of the lymphocytic choriomeningitis virus (LCMV) glycoprotein together with a neutralizing antibody
Shane Crotty receives AAI-BioLegend Herzenberg Award for B cell research
Crotty has advanced vaccine research and tested new strategies for stopping HIV, COVID-19
LJI scientists reflect on what it means to make the “Highly Cited” list
A record number of LJI researchers have been named to the 2022 list, including two early career scientists
The longer the bootcamp, the better the antibodies
LJI scientists test new vaccine strategy to help the body target HIV
LJI scientists publish first head-to-head comparison of four COVID-19 vaccines
New investigation reveals the strength of T cell, B cell, and antibody responses over time
LJI Professor Shane Crotty elected to the American Academy of Microbiology
“This is a real honor. The ASM is an outstanding organization.”
Current vaccines teach T cells to fight Omicron
New LJI study shows how the fully vaccinated respond to a range of SARS-CoV-2 variants
New vaccine ingredient shows promise
Most vaccines include particles called adjuvants. But not all adjuvants are created equal.
Six LJI scientists named “Highly Cited Researchers”
The international recognition reflects how LJI research is valued by scientific peers
Lungs of COVID-19 survivors teem with virus-fighting ‘memory’ cells
Even elderly survivors show a strong, persistent immune memory
Moderna COVID-19 vaccine spurs lasting immune response
Immune system memory stays strong 6+ months post-vaccination, similar to responses in recovered COVID-19 patients
Shane Crotty achieves “World Expert” status for vaccine research
Professor Shane Crotty, Ph.D. , of the La Jolla Institute for Immunology (LJI), has earned the distinction of “World Expert” in vaccine research. This ranking is based on Expertscape‘s PubMed-based algorithms, which place Crotty in the top 0.1% of scholars publishing information…
Can we stretch existing Covid vaccines to inoculate more people? Experts are divided
With the global supply of Covid-19 vaccine still woefully inadequate, vaccine makers are scouring the pharmaceutical landscape for partners to ramp up manufacturing
Sydney Ramirez investigates a lingering COVID-19 question
New A.P. Giannini Foundation Fellowship opens the door to an in-depth look at SARS-CoV-2 infections
In-Depth: San Diego’s most influential COVID-19 researchers
Throughout the pandemic, scientists in San Diego have made big contributions
In-Depth: La Jolla Institute takes comprehensive look at COVID-19 immunity
Study compares four vaccines and natural immunity
In mutant variants, has the coronavirus shown its best tricks?
The rapid rise in different parts of the world of deadly, more infectious coronavirus variants that share new mutations is leading scientists to ask a critical question
The Shapeshifting Virus
Coronavirus: The Evidence
The Future of the Coronavirus? An Annoying Childhood Infection
Once immunity is widespread in adults, the virus rampaging across the world will come to resemble the common cold, scientists predict.
Covid-19 immunity likely lasts for years
A new study shows immune cells primed to fight the coronavirus should persist for a long time after someone is vaccinated or recovers from infection.
Protective immunity against SARS-CoV-2 could last eight months or more
Why declining antibodies don't spell disaster for long-lasting immunity
Inside the labs of three leading San Diego scientists
LJI Professors Shane Crotty, Ph.D., Bjoern Peters, Ph.D., and Alessandro Sette, Dr. Biol. Sci., were named “Highly Cited Researchers” this week by Clarivate.
The End of the Pandemic Is Now in Sight
A year of scientific uncertainty is over. Two vaccines look like they will work, and more should follow.
Immunity to the Coronavirus May Last Years, New Data Hint
Blood samples from recovered patients suggest a powerful, long-lasting immune response, researchers reported.
Coronavirus Immunity May Last Years, Possibly Even Decades, Study Suggests
Immunity to the novel coronavirus may last eight months or longer, according to a new study authored by respected scientists at leading labs, which found that individuals who recovered from the coronavirus developed “robust” levels of B cells and T cells (necessary for fighting off the virus) and “these cells may persist in the body for a very, very long time.”
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
Finding may help explain why people 65 and above face a higher risk of falling critically ill with COVID-19
Beating HIV and COVID-19 may depend on tweaking vaccine molecules
LJI and Scripps Research scientists tackle the problem of antigen valency
Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic?
New research suggests that some of us may be partially protected due to past encounters with common cold coronaviruses
